OBJECTIVE -Current guidelines recommend annual retinopathy screening 2 years after onset (for pubertal-onset type 1 diabetes) and after 5 years (or age 11, whichever is earlier) for prepubertal onset. Our aim was to describe the natural history of retinopathy and to explore optimal retinal screening intervals for children and adolescents (aged Ͻ20 years) screened according to these guidelines.
T o date there are no studies specifically addressing the frequency of screening for diabetic retinopathy in children and adolescents. Current annual screening recommendations for the pediatric population are based on national (1,2) and international consensus (3) (4) (5) . In adults with both type 1 (6) and type 2 (7) diabetes without retinopathy, longer screening intervals are now being recommended subsequent to data from the Liverpool Diabetic Eye Study.
Loss of vision and blindness in persons with diabetes can be delayed or prevented by maintenance of good metabolic control and by early detection and treatment of vision-threatening retinopathy by regular eye examinations and timely intervention with laser treatment or through surgery in cases of advanced retinopathy (8 -11) .
To quantify screening intervals, it is important to understand the prevalence and natural history of retinopathy and to relate recommendations appropriately to the pediatric and adolescent population. Whereas there is a real and definite risk of blindness on a worldwide scale, it is rare to see more than background retinopathy in children and adolescents in developed countries.
In Australia, the prevalence of retinopathy, detected by stereoscopic fundal photography was reported to be 42% (no patient had more than mild background retinopathy) in a clinic population of adolescents with type 1 diabetes (12) . In Europe and America, the reported prevalence in those screened by stereoscopic fundal photography varies from 10 to 35% (13) (14) (15) . Of the many risk factors considered, longer duration of diabetes and poor glycemic control have been consistently reported as independent risk factors for retinopathy in children and adolescents (12,13,16 -21) . In a longitudinal cohort, we aim to describe the natural history of retinopathy and to explore optimal retinal screening intervals for children and adolescents screened according to current consensus guidelines (annual screening 2 years after onset for pubertal-onset type 1 diabetes and after 5 years or age 11, whichever is earlier, for prepubertal onset).
RESEARCH DESIGN AND
METHODS -Included in this analysis were 668 children and adolescents with type 1 diabetes who had retinal screening at the Diabetes Complications Assessment Service at The Children's Hospital at Westmead. Patients were included if they had a baseline retinal screening performed between 1990 and
2002 and at least one follow-up retinal assessment before 20 years of age.
Retinopathy was assessed using stereoscopic fundal photography of seven fields. The stereophotographs were taken with a Topcon Fundus Camera (TRC 50-VT; Tokyo Optical, Tokyo, Japan) after dilatation of the pupils with 1% cyclopentolate and 2.5% phenylephrine. Nonsimultaneous photographic pairs were taken of seven standardized fields in each eye and then viewed with a Donaldson Stereoviewer providing a threedimensional representation of the fundus and enabling microaneurysms to be more easily distinguished from hemorrhages and artifacts.
Baseline and follow-up photographs from the entire set of 668 patients were graded by an ophthalmologist. A second grader also independently assessed 547 retinal photographs from 208 patients (31% of patients). Results were compared, and when retinopathy levels differed, both graders reviewed the photographs to reach consensus. When necessary, a grading supervisor was used to adjudicate. Agreement between the two graders was assessed by calculating a weighted score using quadratic weights. The value was 0.8, which indicates good agreement between graders.
The Early Treatment Diabetic Retinopathy Study adaptation of the modified Airlie House classification of diabetic retinopathy was used (22, 23) . Retinopathy levels for each eye were classified as follows: level 10, no retinopathy; level 21, at least one microaneurysm or hemorrhage; level 31, microaneurysm plus one or more hemorrhage, exudate, venous bead, or loop; and level 41, moderately severe nonproliferative retinopathy. The level of retinopathy of the most severely affected eye was used for this analysis.
The ophthalmological assessment also included measurement of visual acuity, slit lamp examination of the anterior segment, and direct ophthalmoscopy. The following clinical and laboratory parameters were recorded at the time of each eye examination: height, weight, pubertal staging, blood pressure, and HbA 1c .
Statistical methods
The statistical software SPIDA (Statistical Computing Laboratory, Sydney, Australia) was used for data analysis. Retinopathy progression (increase in the retinopathy level or a new occurrence of retinopathy) and regression (reduction in the retinopathy grading either to normal or a less severe grade) were assessed 1-2 years after the initial assessment (baseline). To include all assessments in longitudinal data analysis, generalized estimating equations (GEEs) were used to compare risk of retinopathy at yearly intervals to that at baseline, adjusting for effect of HbA 1c . Analyses were stratified by groups: 1) the whole study group; 2) older and younger subgroups; and 3) higher-risk groups. The higher-risk groups were those with diabetes duration Ͼ10 years or HbA 1c Ͼ10% at any screening visit. Statistical significance was taken as P Ͻ 0.05. RESULTS -The patients were divided into two age-groups at baseline: Ͻ11 years at first retinopathy screening (n ϭ 50, median HbA 1c 8.5%, range 8.0 -9.2%) and Ն11 years at first retinopathy screening (n ϭ 618, median HbA 1c 8.7%, range 8.0 -9.5%). The prevalence of retinopathy at baseline screening was 16% (Ͻ11-year-old group) and 22% (Ն11-year-old group). Overall, 136 of 668 patients had retinopathy at baseline screening (101 had level 21, 32 had level 31, and 3 had level 41). One to 2 years later, in the Ͻ11-year-old group, retinopathy regressed in 80% but progressed in none. In the Ն11-year-old group retinopathy regressed in 36% and progressed in 13%. None of the 668 patients had proliferative retinopathy, and none required laser therapy or surgery. All three patients with level 41 detected at baseline screening had regression of retinopathy by the next retinal screening. Using GEEs, at 1-year follow-up, there was no significant increase in retinopathy in the older or younger group. Retinopathy increased significantly after 2 years from the first eye assessment in the older group (P ϭ 0.003) but not until 6 years in the younger group (P ϭ 0.01) ( Table 1 ). This effect was independent of HbA 1c . After the second eye assessment, retinopathy did not increase significantly until 3 years later in the older group (P ϭ 0.028) and until 6 years later in the younger group (P ϭ 0.014). This unexpected result may be explained by the decreasing sample size as we move further away from the baseline retinopathy screening event.
In the higher-risk groups (Ͼ10 years of diabetes duration or HbA 1c Ͼ10% at any screening), at 1-year follow-up there was no significant increase in retinopathy. In the group with HbA 1c Ͼ10% (documented at any screening), retinopathy increased significantly after 2 years (P ϭ 0.001) but not until 3 years in the group whose HbA 1c was always Յ10% (P ϭ 0.003). Although patients with diabetes duration of Ͼ10 years were less likely to have an improvement in the level of retinopathy after 1 year (Table 2) , there was still no significant increase in retinopathy at 1-year follow-up. The progression and regression patterns of retinopathy from first to last screening are demonstrated in Fig. 1 . The median duration between the first and the last assessment was 3.1 years (interquartile range 2.0 -4.4, range 0.5-8.6).
CONCLUSIONS -The current recommendations for retinopathy screening in children and adolescents are based on consensus viewpoint. The majority of professional bodies have adopted similar viewpoints and recommend annual reti- nopathy screening beginning 2 years after onset (for pubertal-onset type 1 diabetes) and after 5 years (or age 11, whichever is earlier) for prepubertal onset (1-3). The Canadian guidelines recommend annual screening in those Ͼ15 years of age or after 5 years of diabetes (4). The American Academy of Pediatrics recommends annual screening beginning 3-5 years after diagnosis if Ͼ9 years of age (5) . Although the American Diabetes Association recommends annual retinopathy screening for adults with type 1 diabetes (24), some professional bodies recommend biennial screening in adulthood (25, 26) . In the U.K., longer screening intervals are now being recommended for adults with both type 1 and type 2 diabetes who do not have retinopathy at baseline screening (6,7). We were surprised to see that the prevalence of retinopathy had decreased in our clinic population. In 1994 we reported an overall prevalence of any retinopathy of 42% in those patients screened between 1989 and 1992 (12) . The prevalence in the currently reported group is 16% in the younger group and 22% in the older group (Ͻ11 years old and Ն11 years old at baseline screening).
This could be a direct consequence of the implementation of intensive insulin therapy following the Diabetes Control and Complications Trial (DCCT) results in 1993. Although the metabolic benefits of intensive therapy are not reflected in the median HbA 1c of the currently reported group (8.6%) compared with 8.2% in the 1994 series, the currently reported group has a higher percentage of patients receiving multiple daily injections (33% compared with 13% in 1994, P Ͻ 0.0001), rather than twice-daily injections (67% compared with 87% in 1994, P Ͻ 0.0001). Therefore, the decreased prevalence of retinopathy may be due to fewer glucose excursions. We wondered if the decrease in prevalence of retinopathy was a result of the screening process itself; however, one would still expect there to be a metabolic correlate of such an improvement.
We wanted to update the current guidelines for retinopathy by specifically addressing the dilemmas facing the clinician deciding when to repeat the screening. To address these specific clinical dilemmas, we separately analyzed the Ͻ11-year-olds and Ն11-year-olds (as a surrogate cutoff for prepubertal and pubertal children, respectively). The current pediatric guidelines make different recommendations for prepubertal and pubertal children. Because there was no significant increase in the prevalence of any retinopathy after 1 year, it is unnecessary to repeat the screening annually. There was a significant increase in retinopathy after 2 years in the older group and after 6 years in the younger group. Although retinopathy did progress, the highest grade of retinopathy detected was level 41 (in 3 of 668 patients), and neither of these required treatment. From these results we believe that clinically significant, vision-threatening or treatmentrequiring retinopathy will not be missed by extending the interval to 2 years.
Because diabetes duration and metabolic control have been consistently reported as risk factors for retinopathy and to further address real life clinical dilemmas, we analyzed specific higher-risk groups. Again, in this analysis, we found that after 1-year follow-up there was no significant increase in retinopathy. In the group with HbA 1c Ͼ10% (documented at any screening), retinopathy increased significantly after 2 years but not until 3 years in the group whose HbA 1c was always Յ10%. Although patients with dia- betes duration Ͼ10 years were less likely to have an improvement in the level of retinopathy after 1 year, there was still no significant increase in retinopathy at 1-year follow-up. Although these results suggest that it is safe to extend the screening interval in these higher-risk groups, our definition of what constitutes high risk is arbitrary. As the risk of complications increase directly with increased diabetes duration and HbA 1c , we feel that caution should be used for anyone who the clinician deems to be at higher risk and in whom follow-up is likely to be inconsistent. Direct ophthalmoscopy, indirect ophthalmoscopy, nonmydriatic fundal photography, and mydriatic fluorescein angiography or mydriatic stereoscopic fundal photography (MSFP) are used to screen for retinopathy. The DCCT showed that MSFP is as sensitive as mydriatic fluorescein angiography in detection of retinopathy, and both of these methods are more sensitive than clinical examination by direct ophthalmoscopy alone (27) . Our group found MSFP to be four times more sensitive than direct ophthalmoscopy alone in the detection of early background retinopathy (12) . A recent systematic review looking at the effectiveness of retinopathy screening methods concluded that MSFP is the most sensitive method; however, direct ophthalmoscopy may be useful when photographs are ungradeable or for opportunistic case findings (28) . Therefore, when resources permit, we recommend MSFP as the screening method of choice.
In keeping with data published previously from an audit of glycemic control in New South Wales and the Australian Capital Territory (29) , ϳ75% of the currently reported group achieved an HbA 1c Ͻ10%. Therefore, this recommendation may be applicable in a large proportion of our clinic population (depending on retinopathy screening results) and has significant resource utilization implications.
Current diabetes education programs coupled with the "fear of complications" may not be achieving optimum motivation for glycemic control. The retinopathy screening process itself may be a therapeutic, educational, and motivational event contributing to the reduction in retinopathy, which we have documented from 1994 to 2004. While redefining the appropriate screening frequency, we should not lose sight of these other potential benefits of screening.
The reason to increase the screening interval from 1 to 2 years are resource based and also are an attempt to resolve the inconsistency between existing pediatric and recent adult guidelines.
From our data we can say that in Australia and other developed countries with health care standards similar to those of Australia it is extremely unlikely that severe, vision-threatening or treatmentrequiring retinopathy would be missed by extending the screening interval to 2 years for children and adolescents who access specialist diabetes services. In younger children the next screening interval could be Ͼ2 years later, provided there are no other risk factors. Individuals with other risk factors, poor glycemic control, or long diabetes duration should continue to be screened annually. When significant retinopathy is detected, screening should be annually or more frequently (depending on the severity of the retinopathy). In developing countries, especially when there is inadequate supply of insulin and in countries with different health care standards to Australia the onset of retinopathy may be earlier and the condition may progress more quickly. Therefore, these recommendations should be interpreted with caution outside of this setting.
